Skip to content
2000
Volume 26, Issue 9
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Purpose

This research aimed to establish a population pharmacokinetic (PPK) model for busulfan (Bu) in Chinese pediatric patients with thalassemia major. We analyzed pharmacokinetic (PK) parameter variability and explored potential covariates affecting Bu disposition using patient data. These findings are intended to support the optimization and personalization of Bu dosage regimens for children with thalassemia major.

Methods

Concentration-time samples were collected retrospectively from 62 pediatric patients with thalassemia major. These patients had previously received intravenous Bu as a preparatory regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). A PPK model of Bu was developed through nonlinear mixed-effects modeling. This modeling process, conducted using NONMEM software, concurrently involved data analysis and examination of the effect of covariates on Bu pharmacokinetics. For validation purposes, the resulting model was evaluated against an external dataset consisting of 20 individuals.

Results

The pharmacokinetic results were optimally analyzed using a model that incorporated a one-compartment model with first-order elimination. Body surface area (BSA) was subsequently identified as the most significant factor influencing both Bu clearance (CL) and volume of distribution (V). Diagnostic evaluations, encompassing goodness-of-fit plots, normalized prediction distribution errors, and visual predictive checks, confirmed the satisfactory fit and predictability of the final PPK model. Moreover, prediction-based diagnostic indices (MDPE%, 15.75; MAPE%, 22.26; F20%, 45.71; and F30%, 58.57) from external validation showed that no significant bias was detected when comparing the model's predicted concentrations against the observed data.

Conclusion

The present study developed the first PPK model characterizing the pharmacokinetics of Bu specifically in children with thalassemia major. This study's final PPK model demonstrated that BSA was the key predictive covariate for CL and V.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002402673251003055700
2025-10-15
2026-02-22

  • From This Site

    /content/journals/cdm/10.2174/0113892002402673251003055700
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BairdD.C. BattenS.H. SparksS.K. Alpha- and Beta-Thalassemia: Rapid evidence review.Am. Fam. Physician20221053272280 35289581
     [Google Scholar]
  2. SonkawadeN.D. KinikarA.A. KulkarniR.K. DawreR.M. ValviC.T. KamathP.A. Screening of extended family members of Thalassemia major children as a Thalassemia preventive strategy.Ethiop. J. Health Sci.20223261203121010.4314/ejhs.v32i6.18 36475260
     [Google Scholar]
  3. LiC.G. LiC.F. LiQ. LiM. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province.Hemoglobin200933529630310.3109/03630260903211698 19814675
     [Google Scholar]
  4. LaiK. HuangG. SuL. HeY. The prevalence of thalassemia in mainland China: Evidence from epidemiological surveys.Sci. Rep.20177192010.1038/s41598‑017‑00967‑2 28424478
     [Google Scholar]
  5. XuX. WuX. Epidemiology and treatment of beta Thalassemia major in China.Pediatr. Investig.202041434710.1002/ped4.12154 32851341
     [Google Scholar]
  6. OikonomopoulouC. GoussetisE. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe.Bone Marrow Transplant.202156122882288810.1038/s41409‑021‑01461‑0 34531544
     [Google Scholar]
  7. AbbasiN. VadnaisB. KnutsonJ.A. BloughD.K. KellyE.J. O’DonnellP.V. DeegH.J. PawlikowskiM.A. HoR.J.Y. McCuneJ.S. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.J. Clin. Pharmacol.201151101429143810.1177/0091270010382915 21135089
     [Google Scholar]
  8. PalmerJ. McCuneJ.S. PeralesM.A. MarksD. BubaloJ. MohtyM. WingardJ.R. PaciA. HassanM. BredesonC. PidalaJ. ShahN. ShaughnessyP. MajhailN. SchriberJ. SavaniB.N. CarpenterP.A. Personalizing busulfan-based conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.Biol. Blood Marrow Transplant.201622111915192510.1016/j.bbmt.2016.07.013 27481448
     [Google Scholar]
  9. HeZ. WangY. ZhuH. ChenY. YeC. OuJ. Junyan Yu,X. Population pharmacokinetics of busulfan in pediatric patients: Optimization of a four‐times‐daily dosing regimen based on EBMT recommendations.Pediatr. Blood Cancer2025e31969e3196910.1002/pbc.3196940781807
     [Google Scholar]
  10. NguyenL. FullerD. LennonS. LegerF. PuozzoC.I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Bone Marrow Transplant.2004331097998710.1038/sj.bmt.1704446 15064687
     [Google Scholar]
  11. SchreibK.M. BrämD.S. ZeilhoferU.B. MüllerD. GüngörT. KrämerS.D. Hauri-HohlM.M. Population pharmacokinetic modeling for twice-daily intravenous busulfan in a large cohort of pediatric patients undergoing hematopoietic stem cell transplantation—A 10-year single-center experience.Pharmaceutics20231611310.3390/pharmaceutics16010013 38276491
     [Google Scholar]
  12. SavicR.M. CowanM.J. DvorakC.C. PaiS.Y. PereiraL. BartelinkI.H. BoelensJ.J. BrediusR.G.M. WynnR.F. CuvelierG.D.E. ShawP.J. SlatterM.A. Long-BoyleJ. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.Biol. Blood Marrow Transplant.201319111608161410.1016/j.bbmt.2013.08.014 24029650
     [Google Scholar]
  13. Del Valle-MorenoP. Suarez-CasillasP. Mejías-TruebaM. Ciudad-GutiérrezP. Guisado-GilA. Gil-NavarroM. Herrera-HidalgoL. Model-informed precision dosing software tools for dosage regimen individualization: A scoping review.Pharmaceutics2023157185910.3390/pharmaceutics15071859 37514045
     [Google Scholar]
  14. NeroutsosE. Nalda-MolinaR. PaisiouA. ZisakiK. GoussetisE. SpyridonidisA. KitraV. GrafakosS. ValsamiG. DokoumetzidisA. Development of a population pharmacokinetic model of busulfan in children and evaluation of different sampling schedules for precision dosing.Pharmaceutics202214364710.3390/pharmaceutics14030647 35336021
     [Google Scholar]
  15. BartelinkI.H. LalmohamedA. BognarT. NurE. BoelensJ.J. Optimizing allogeneic hematopoietic cell transplantation outcomes through busulfan PK/PD.Transplant. Cell. Ther.202531847747910.1016/j.jtct.2025.07.008 40759455
     [Google Scholar]
  16. BartelinkI.H. van KesterenC. BoelensJ.J. EgbertsT.C.G. BieringsM.B. CuvelierG.D.E. WynnR.F. SlatterM.A. ChiesaR. DanhofM. KnibbeC.A.J. Predictive performance of a busulfan pharmacokinetic model in children and young adults.Ther. Drug Monit.201234557458310.1097/FTD.0b013e31826051bb 22972539
     [Google Scholar]
  17. TrameM.N. BergstrandM. KarlssonM.O. BoosJ. HempelG. Population pharmacokinetics of busulfan in children: Increased evidence for body surface area and allometric body weight dosing of busulfan in children.Clin. Cancer Res.201117216867687710.1158/1078‑0432.CCR‑11‑0074 21918171
     [Google Scholar]
  18. BleyzacN. SouilletG. MagronP. JanolyA. MartinP. BertrandY. GalambrunC. DaiQ. MaireP. JelliffeR.W. AulagnerG. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.Bone Marrow Transplant.200128874375110.1038/sj.bmt.1703207 11781625
     [Google Scholar]
  19. TseW.T. DuerstR. SchneidermanJ. ChaudhuryS. JacobsohnD. KletzelM. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Bone Marrow Transplant.200944314515610.1038/bmt.2008.437 19182832
     [Google Scholar]
  20. ChoiB. KimM.G. HanN. KimT. JiE. ParkS. KimI.W. OhJ.M. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.Pharmacogenomics201516141585159410.2217/pgs.15.98 26419450
     [Google Scholar]
  21. SalvarisR. SalmanS. O’HalloranS. JoyceD. MathewN. CooneyJ. WrightM. CannellP. PurtillD. Evaluating the efficacy, toxicity and pharmacokinetic profile of oral busulfan in allogeneic stem cell transplant patients.Blood Cell Ther.202252616810.31547/bct‑2021‑019 36710948
     [Google Scholar]
  22. YangY. WangC. ChenY. WangX. JiaoZ. WangZ. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients.Eur. J. Pharm. Sci.202318610641610.1016/j.ejps.2023.106416 37119861
     [Google Scholar]
  23. NadellaT.R. SuryadevaraV. LankapalliS.R. MandavaV.B.R. BandarupalliD. LC–MS/MS method development for quantification of busulfan in human plasma and its application in pharmacokinetic study.J. Pharm. Biomed. Anal.201612016817410.1016/j.jpba.2015.12.024 26736033
     [Google Scholar]
  24. XiaoY. LiX. FuX. A rapid and simple LC–MS/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT).Clin. Chim. Acta201847919019510.1016/j.cca.2018.01.020 29341904
     [Google Scholar]
  25. LiuM. QinJ. ChuX. ChenN. JieQ. ZhengS. Population pharmacokinetic study and application of ticagrelor and AR-C124910XX after percutaneous coronary intervention in Chinese patients with acute coronary syndromeInt. J. Clin. Pharmacol. Ther.202462941242210.5414/CP204550 39037109
     [Google Scholar]
  26. WangX. WangY. YaoF. ChenS. HouY. ZhengZ. LuoJ. QiuB. LiZ. WangY. WuZ. LanJ. ChenC. Pharmacokinetics of Linezolid dose adjustment for creatinine clearance in critically ill patients: A multicenter, prospective, open-label, observational study.Drug Des. Devel. Ther.2021152129214110.2147/DDDT.S303497 34040351
     [Google Scholar]
  27. CaiR. ZhangL. WuT. HuangY. LuJ. HuangT. WuY. WuD. QiJ. NiuL. XiaoY. ChenX. LiuY. LuoY. LiuT. Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation.Eur. J. Clin. Pharmacol.202480568569610.1007/s00228‑024‑03641‑5 38329479
     [Google Scholar]
  28. GrassedonioE. IncorvaiaL. GuarneriM. GuagniniF. MidiriM. Prevention of post-contrast kidney injury in patients with cancer.Drugs Context20241311010.7573/dic.2023‑11‑2 38510312
     [Google Scholar]
  29. ZhaoC.Y. JiaoZ. MaoJ.J. QiuX.Y. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Br. J. Clin. Pharmacol.201681589190710.1111/bcp.12830 26574188
     [Google Scholar]
  30. ShaoD. LiJ. HuT. ZhangZ. Zhang liJ. CaoJ. FengS. TangR. ZhongD. SongZ. YueM. HuM. XuanL. ZhaiM. ZhangH. WangX. ShiX. LiuR. Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring.Bone Marrow Transplant.202257347347810.1038/s41409‑021‑01545‑x 35039622
     [Google Scholar]
  31. KishimotoK. HasegawaD. IrieK. OkadaA. NakamuraS. TamuraA. YamamotoN. KozakiA. SaitoA. IshidaT. FukushimaS. KosakaY. Pharmacokinetic analysis for model‐supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients.Pediatr. Transplant.2020244e1369610.1111/petr.13696 32196880
     [Google Scholar]
  32. GazievJ. NguyenL. PuozzoC. MozziA.F. CasellaM. Perrone DonnorsoM. GravinaP. SodaniP. MarzialiM. IsgròA. SimoneM.D. AndreaniM. FormosaA. TestiM. FedericiG. BernardiniS. LucarelliG. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.Blood2010115224597460410.1182/blood‑2010‑01‑265405 20237319
     [Google Scholar]
  33. FaraciM. TinelliC. LaninoE. GiardinoS. LeoniM. FerrettiM. CastagnolaE. BrogliaM. De SilvestriA. Di MartinoD. BartoliA. Monitoring of busulphan concentrations in children undergone hematopoietic stem cell transplantation: Unicentric experience over 10 years.Eur. J. Drug Metab. Pharmacokinet.201843217318110.1007/s13318‑017‑0431‑0 28801891
     [Google Scholar]
  34. TakahashiT. JaberM.M. BrownS.J. Al-KofahiM. Population pharmacokinetic model of intravenous busulfan in hematopoietic cell transplantation: Systematic review and comparative simulations.Clin. Pharmacokinet.202362795596810.1007/s40262‑023‑01275‑x 37415003
     [Google Scholar]
  35. PoonkuzhaliB. SrivastavaA. QuerninM.H. DennisonD. AigrainE.J. KanagasabapathyA.S. KrishnamoorthyR. ChandyM. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.Bone Marrow Transplant.199924151110.1038/sj.bmt.1701814 10435727
     [Google Scholar]
  36. Gürlek GökçebayD. AzikF. OzbekN. IsikP. AvciZ. TavilB. KaraA. TuncB. Clinical comparison of weight‐ and age‐based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.Pediatr. Transplant.201519330731510.1111/petr.12430 25661259
     [Google Scholar]
  37. YuanJ. SunN. FengX. HeH. MeiD. ZhuG. ZhaoL. Optimization of busulfan dosing regimen in pediatric patients using a population pharmacokinetic model incorporating GST mutations.Pharm. Genomics Pers. Med.20211425326810.2147/PGPM.S289834 33623415
     [Google Scholar]
  38. McCuneJ.S. BemerM.J. BarrettJ.S. Scott BakerK. GamisA.S. HolfordN.H.G. Busulfan in infant to adult hematopoietic cell transplant recipients: A population pharmacokinetic model for initial and Bayesian dose personalization.Clin. Cancer Res.201420375476310.1158/1078‑0432.CCR‑13‑1960 24218510
     [Google Scholar]
  39. PawlowskaA.B. BlazarB.R. AngelucciE. BaroncianiD. ShuX.O. BostromB. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.Bone Marrow Transplant.1997201191592010.1038/sj.bmt.1701001 9422469
     [Google Scholar]
  40. MahomedradjaR.F. BognàrT. van SchieK.E. KuipersI.T. de WitteM.A. KuballJ.H.E. NurE. WilhelmB.J. Heerma van] ] Voss, M.R.; Franken, L.; Lalmohamed, A.; Swart, E.N.L.; de Leeuw, D.C.; Bartelink, I.H. Model‐informed precision dosing of busulfan for children and adults undergoing allogeneic hematopoietic stem cell transplantation: A critical evaluation of current PK models and dose recommendations.Clin. Pharmacol. Ther.2025118372373410.1002/cpt.3748 40545743
     [Google Scholar]
  41. PuangpetchA. ThomasF. AnurathapanU. PakakasamaS. HongengS. RachanakulJ. PrommasS. NuntharadthanaphongN. ChatelutÉ. SukasemC. Le LouedecF. Model-informed precision dosing of intravenous busulfan in Thai pediatrics undergoing hematopoietic stem cell transplantation.Ther. Drug Monit.202446677878510.1097/FTD.0000000000001225 38758634
     [Google Scholar]
  42. KimM.G. KwakA. ChoiB. JiE. OhJ.M. KimK. Effect of glutathione S‐transferase genetic polymorphisms on busulfan pharmacokinetics and veno‐occlusive disease in hematopoietic stem cell transplantation: A meta‐analysis.Basic Clin. Pharmacol. Toxicol.2019124669170310.1111/bcpt.13185 30511436
     [Google Scholar]
  43. GibbsJ.P. MurrayG. RislerL. ChienJ.Y. DevR. SlatteryJ.T. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.Cancer Res.1997572455095516 9407960
     [Google Scholar]
  44. AnsariM. Huezo-DiazP. RezguiM.A. MarktelS. DuvalM. BittencourtH. CappelliB. KrajinovicM. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in Thalassemia pediatric patients.Bone Marrow Transplant.201651337738310.1038/bmt.2015.321 26691424
     [Google Scholar]
  45. NavaT. KassirN. RezguiM.A. UppugunduriC.R.S. Huezo-Diaz CurtisP. DuvalM. ThéoretY. DaudtL.E. LitalienC. AnsariM. KrajinovicM. BittencourtH. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.Br. J. Clin. Pharmacol.20188471494150410.1111/bcp.13566 29469189
     [Google Scholar]
  46. NishikawaT. YamaguchiH. IkawaK. NakayamaK. HigashiE. MiyaharaE. AbematsuT. NakagawaS. KodamaY. TanabeT. ShigemiA. ShinkodaY. OkamotoY. TakedaY. KawanoY. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.Pediatr. Int.201961655856510.1111/ped.13859 30963629
     [Google Scholar]
  47. Long-BoyleJ.R. SavicR. YanS. BartelinkI. MusickL. FrenchD. LawJ. HornB. CowanM.J. DvorakC.C. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: A model-based dosing algorithm for personalized therapy and implementation into routine clinical use.Ther. Drug Monit.201537223624510.1097/FTD.0000000000000131 25162216
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002402673251003055700
Loading
A Population Pharmacokinetics Model of Busulfan in Pediatric Patients with Thalassemia Major
Current Drug Metabolism 26, 618 (2025); https://doi.org/10.2174/0113892002402673251003055700
/content/journals/cdm/10.2174/0113892002402673251003055700
/content/journals/cdm/10.2174/0113892002402673251003055700
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Busulfan; hematopoietic stem cell transplantation; individualized therapy; thalassemia major; therapeutic drug

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test